News

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...